Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

okay everybody knows RESISTENCE happens in CML with

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
ariadndndough  Member Profile
 
Followed By 34
Posts 4,542
Boards Moderated 0
Alias Born 12/27/07
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2014 4:06:48 PM
ARIAD annuncia l'adozione di un'opinione finale per Iclusig da parte del Comitato europeo per i medicinali per uso umano "Business Wire" - 10/24/2014 10:55:00 AM
ARIAD annonce l'adoption de l'avis définitif sur l’Iclusig par le Comité des médicaments à usage humain en Europe "Business Wire" - 10/24/2014 8:48:00 AM
ARIAD meldet Bestätigung der positiven abschließenden Stellungnahme zu Iclusig durch den Ausschuss für Humanarzneimittel i... "Business Wire" - 10/24/2014 8:23:00 AM
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe "Business Wire" - 10/24/2014 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/17/2014 4:23:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/16/2014 4:26:18 PM
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results "Business Wire" - 10/15/2014 7:35:00 AM
ARIAD rende nota la raccomandazione per Iclusig da parte del Comitato di valutazione dei rischi per la farmacovigilanza dell'... "Business Wire" - 10/10/2014 3:43:00 PM
Ariad annonce les recommandations du comité pour l’évaluation des risques en matière de pharmacovigilance de l’Agence ... "Business Wire" - 10/10/2014 10:12:00 AM
ARIAD erhält befürwortende Stellungnahme für Iclusig vom Beratenden Ausschuss für Risikobewertung im Bereich der Pharmako... "Business Wire" - 10/10/2014 7:49:00 AM
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency "Business Wire" - 10/10/2014 7:44:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/10/2014 6:00:32 AM
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology "Business Wire" - 10/6/2014 7:35:00 AM
AP26113 d’ARIAD désigné par la FDA traitement révolutionnaire contre le cancer bronchique non à petites cellules ALK+ r... "Business Wire" - 10/3/2014 12:24:00 PM
ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib "Business Wire" - 10/2/2014 7:35:00 AM
ARIAD présente de nouveaux résultats de son étude clinique sur l'AP26113 chez des patients atteints d'un cancer du poumon ... "Business Wire" - 9/30/2014 10:18:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2014 4:05:48 PM
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer "Business Wire" - 9/29/2014 7:35:00 AM
ARIAD stellt aktualisierte klinische Ergebnisse zu AP26113 bei Patienten mit ALK-positivem nicht-kleinzelligem Lungenkrebs vor "Business Wire" - 9/29/2014 7:35:00 AM
Amended Statement of Changes in Beneficial Ownership (4/a) "Edgar (US Regulatory)" - 9/18/2014 4:30:05 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/18/2014 4:06:51 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/11/2014 4:41:01 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/11/2014 4:39:27 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/11/2014 4:38:33 PM
ariadndndough   Wednesday, 08/28/13 01:32:37 PM
Re: None
Post # of 55502 
okay everybody knows RESISTENCE happens in CML with the other drugs.

please read this and then know what PONA does. it will take some more time maybe 1-2 more years to play out.

but if you know what you own here the prize is great.

taken from last nights 100 page pona paper. i suggest all read it.

Problem statement
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder representing about 15% to 20% of adult leukaemias (Deininger et al, 2000; Pinilla-Ibarz et al, 2008). The underlying cause of CML is the BCR-ABL fusion oncoprotein, which results from a reciprocal t (9; 22) chromosomal translocation in hematopoietic stem cells. This chromosomal abnormality, known as the Philadelphia chromosome (Ph+), is present in about 95% of all patients with CML, as well as about 20% to 25% of adult patients with acute lymphoblastic leukaemia (ALL). The translocation leads to the fusion of the Breakpoint Cluster Region (BCR) coding sequence with the tyrosine kinase coding region of ABL. This fusion event results in the constitutive activation of ABL kinase activity. BCR-ABL activates multiple downstream pathways that contribute to the growth and survival of cells (Hazlehurst et al, 2009).
Chronic myeloid leukaemia is typically a triphasic continuum of disease with a chronic phase (CP-CML), accelerated phase (AP-CML), and blast phase (BP-CML)—characteristics of the disease and prognosis are different for each phase. Chronic is the longest phase, and can last over 10 years in some patients (Padmanabhan et al, 2008). However, if transition to AP-CML occurs, median survival is typically limited to under a year, while patients in BP-CML (which resembles acute leukaemia) usually live for only a few months. Most patients are diagnosed in CP-CML and may be asymptomatic or present with fatigue, anaemia, weight loss, night sweats, or splenomegaly.
Acute lymphoblastic leukaemia (ALL) is a malignant proliferation of lymphoid cells. The majority of cases of ALL show chromosomal and genetic abnormalities, and approximately 25% of adult cases of ALL are Ph+. The presence of the BCR-ABL translocation confers an adverse prognosis (Radich, 2001).
Current treatment guidelines (European LeukemiaNet and National Comprehensive Cancer Network) recommend treatment with Tyrosine Kinase Inhibitors (TKIs). In Europe the following TKIs are currently approved for the treatment of CML and Ph+ ALL: Glivec (imatinib); Sprycel (dasatinib); and Tasigna (nilotinib).
Treatment for CML was significantly advanced in 2001 following the approval of imatinib. Since then, targeted therapy with imatinib in newly diagnosed patients has become standard. With imatinib the complete cytogenetic response (CCyR) rate was reported as 76% (O’Brien et al., 2003). Dasatinib and nilotinib have also been approved for the treatment of patients who are or become resistant to imatinib therapy. These drugs yield complete cytogenetic response rates (CCyR) from 30%-50% (Talpaz et al., 2006; Kantarjian et al., 2006). Resistance to TKI therapy continues to be a significant challenge in the Iclusig
CHMP assessment report
EMA/CHMP/220290/2013
Page 9/100
treatment of CML. At present, there is no standard approach to treat the CML patient who has been treated unsuccessfully with both imatinib and then either with dasatinib or nilotinib.
The best understood mechanism of resistance to TKI therapy is the development of point mutations in the BCR-ABL kinase domain. More than 100 different mutations in the kinase domain of ABL have been discovered and have been shown to be responsible for 40% to 50% of the resistance to existing TKIs (Jabbour et al., 2009). The detection of kinase domain mutations even early in disease is adversely prognostic (Khorashad et al., 2008), is higher in accelerated phase (AP)/blast phase (BP) compared with chronic phase (CP) and increases with the duration of disease (Quintas-Cardama & Cortes, 2008). For patients who fail imatinib therapy, the frequency of BCR-ABL mutations ranges from 40% to 90%, depending on the phase and method of detection (Quintas-Cardama & Cortes, 2008).
The most common single resistant mutation, which occurs in approximately 15% of patients who develop resistance to imatinib (Quintas-Cardama & Cortes, 2008), is a transition point mutation at position 944 of the BCR-ABL gene, resulting in a substitution of isoleucine (I) for threonine (T) at position 315 of the protein: designated T315I, a “gatekeeper” mutation. The T315I mutation accounts for 15%-20% of all mutations observed in refractory CML (Nicolini et al, 2009).
Although dasatinib is effective against some mutations that confer resistance to imatinib therapy, and nilotinib also treats some imatinib-induced mutations, no approved drug inhibits T315I mutation.
However, not all patients who fail therapy carry detectable resistance mutations. Mutations are undetectable in a substantial proportion of patients who fail imatinib. In many of these patients, non BCR ABL driven mechanisms of resistance are likely contributing to resistance.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist